Research programme: macrolide therapeutics - NB Health Laboratory

Drug Profile

Research programme: macrolide therapeutics - NB Health Laboratory

Alternative Names: P 008

Latest Information Update: 13 Sep 2016

Price : $50

At a glance

  • Originator NB Health Laboratory
  • Class Macrolides
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Chronic obstructive pulmonary disease; Sinusitis

Highest Development Phases

  • Research Chronic obstructive pulmonary disease; Sinusitis

Most Recent Events

  • 13 Sep 2016 Early research in Sinusitis in Japan (unspecified route) before September 2016
  • 13 Sep 2016 Early research in Chronic obstructive pulmonary disease in Japan (unspecified route) before September 2016
  • 13 Sep 2016 NB Health Laboratory has patent protection for P 008 (NB Health Laboratory pipeline, September 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top